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Abstract
Objectives The objective of the study was to assess the
association between the quality of drug prescribing based
on three indicator types derived from the DU90% method
and different levels of functioning in pharmacotherapy
audit meetings (PTAMs).
Materials and methods The level of functioning in PTAMs
in 2004 was assessed by a standard questionnaire. Data on
prescriptions in 2004 by the GPs participating in the included
PTAMs were extracted from the database of the Foundation
for Pharmaceutical Statistics. Three types of DU90%
indicators were computed for the seven mostly prescribed
drug classes. With univariate and multivariate analyses of
variance, differences in the results of three types of indicators
for each of the seven drug classes were assessed according to
the levels of PTAMs.
Results For 84 PTAMs with varying levels of functioning,
we found no association between the level of PTAM and the
quality of prescribing for any of the indicators within the
seven drug classes. In general, results gained of all PTAMs
seemed to be high in quality for the aspects measured.
Conclusions It is difficult to define indicators based on the
DU90% method, which can readily distinguish differences
in the quality of drug prescribing between PTAMs with
different levels of functioning. Indicators for prescribing
should specifically meet relevant items in the quality of
prescribing for certain drug classes. Items for classification
of PTAM levels may need some reconsideration.
Keywords Prescribingindicators.Pharmacotherapyaudit
meetings.Druguse90%method
Introduction
In The Netherlands, pharmacotherapy audit meetings
(PTAMs) are established since 1990. These are local
meetings of GPs and community pharmacists to make
agreements on pharmacotherapy based on national guide-
lines and with regard to the costs of medicines to
improve prescribing and dispensing of drugs. Depending
on the local character, these groups differ concerning
participating number of GPs and pharmacists, frequency
and duration of the meetings, choice and the way of
discussing topics and the adherence to agreements made
in the daily practice of prescribing. By this, the
nowadays more than 800 PTAMs in the Netherlands
differ in the quality of functioning. It is to be expected
that PTAMs with strict rules, which meet more regularly
and reach obligatory agreements, will prescribe and
dispense drugs more efficiently with regards to quality
and costs. Research of this association, however, is still
scarce. In The Netherlands, there were two studies with
different results. Muijrers et al. [1] did not find any
association between the quality of prescribing and the
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that PTAMs functioning on a higher level of cooperation
were less susceptible to marketing influences to prescribe
newly introduced drugs, and therefore, showed a higher
quality in prescribing. Regarding these conflicting results,
we decided to investigate the association between the
q u a l i t yo fP T A M sa n dt h eq u a l i t yo fd r u gp r e s c r i b i n g ,
taking into account a number of lessons learnt from the
earlier studies. First, the levels of PTAMs in one of the
earlier studies had been judged by self-made question-
naires [3]. We made use of the routine assessment of the
quality of functioning in PTAMs from 2004 performed
annually by The Dutch Institute for the Proper use of
Medicines (DGV) since 2000 on behalf of the Dutch
Ministry of Health [4, 5]. Second, for the judgement of the
quality of prescribing, we used the drug utilization 90%
(DU90%) method [6]. In Sweden, this method has been
introduced as an inexpensive, flexible and simple manner
to assess the quality of drug prescribing which is
recommended for that aim by the Swedish Medical
Quality Council. The DU90% method focuses on 90% of
the delivered drug volume and supplies three general
quality indicators for prescribing [7]. Third, we applied
the DU90% to each of the seven mostly prescribed groups
of drugs where we expected the influence of PTAMs to
become most obvious. Fourth, we restricted the DU90%
method to first prescriptions, and by this, excluded repeat
prescribing, as changes in prescription behaviour become
better visible in new than ine x i s t i n gd r u gr e g i m e n s[ 8].
Fifth, for the quality of prescribing, we made use of
dispensing data of pharmacies collected by the Foundation
of Pharmaceutical Statistics (SFK). Concerning drug
exposure, pharmacy databases are superior to prescribing
data reflecting the medication actually dispensed [9].
Dispensing data have proven to correlate well with patient
questionnaires on actual drug intake for chronically used
drugs [10]. In this cross-sectional population-based study,
we investigated the association between the quality of
functioning in PTAMs, categorised into four levels by
annual quality assessments, and the quality of prescribing,
measured by the DU90% method with first dispensing of
participating GPs for three indicator types within the
seven mostly prescribed groups of drugs based on
dispensing data.
Materials and methods
Inclusion of PTAMs
In the end of 2005, 257 of the more than 800 PTAMs
were asked to join the study. In stratified selection, 50
PTAMs for each of the four levels (based on the quality
assessment of DGV in 2004) and 57 PTAMs with no
level available were invited. As it is possible that more
than one community pharmacy participates in a PTAM, a
total of 387 pharmacies had to be asked for permission
to use their data in this study. Pharmacists further had to
identify the GPs participating in their PTAM in 2004 by
the anonymous codes from their computer systems. For
this purpose, an online accessible web form was created.
A third precondition for PTAMs to join the study was
that pharmacies had delivered complete dispensing data
to SFK from the year 2004 and from the second half of
2003 to distinguish first prescriptions from repeat
prescribing. The SFK routinely collects dispensing data
from more than 90% of the total of about 1,800
community pharmacies in The Netherlands. These data
include detailed information on drugs dispensed such as
the codes from the anatomic therapeutic chemical (ATC)
system [11] and cost price. Dispensings are linked to the
patients having been prescribed the drug in question.
Patients are identified by an anonymous code, gender and
year of birth, being the only information of the patient
himself. Furthermore, for each dispensing, prescribers can
be identified by speciality, and GPs further have an
anonymous code.
Levels for the quality of functioning of PTAMs
Levels of functioning were assigned by a standard
questionnaire developed by DGV for annual quality
assessments [4, 5]. Six objective criteria were judged by
an expert panel to be most important for cooperation
within PTAMs such as the frequency and duration of the
meetings, a jointly preparation of GPs and pharmacists,
coming to agreements and checking the implementation of
agreements in prescribing practice (Table 1). These
questionnaires were sent to a GP and a pharmacist as the
declared contacts of each PTAM. The results collected for
s i xc r i t e r i ai n2 0 0 4w e r eu s e dt os c a l ea l lP T A M si n t oo n e
of the four different levels of cooperation by an investi-
gator of DGV (Table 2).
Table 1 Six domains for quality assessment of the PTAMs
Parameters
Number of FTO meetings
Median duration of FTO meetings
Joined preparation of GP and pharmacist (yes or no)
Use of feedback information by prescription data concerning
prescribed volume, costs/DDD and preferences in drug choice per
GP (yes or no)
Written down agreements on drug choices (yes or no)
Routine check of adherence to the agreements made with prescription
data (yes or no)
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The DU90% method was applied to the seven groups of
drugs that had more than 4 million prescriptions in 2004:
HMGCoA reductase inhibitors, drugs for acid-related
disorders, antibacterials for systemic use, antidepressants,
benzodiazepine derivatives, drugs for obstructive airway
diseases and oral blood-glucose-lowering drugs (Table 3).
For these groups, only prescriptions of the GPs partici-
pating in the included PTAMs were selected in 2004.
From these, only first dispensings were derived from the
Table 2 Four levels for the quality of functioning of PTAMs
Level Description
Level 1 No structured meetings
Level 2 Frequent meetings without concrete decisions
Level 3 Frequent meetings with concrete decisions, supported by
use of feedback information with prescription data, but
without evaluation of these decisions
Level 4 Frequent meetings with concrete decisions and
evaluation of these decisions
Table 3 Selection of drugs from the seven groups, classification of guideline drugs and non-guideline drugs mostly encountered
Group of drugs ATC Guideline drugs Mostly encountered non-
guideline drugs in our
study population
HMG CoA
reductase inhibitors
C10AA C10AA01, C10AA03 Simvastatin, Pravastatin Fluvastatin,
Rosuvastatin,
Atorvastatin
Drugs for acid-related
diseases
a
A02 A02A, A02BA Antacids, H2-receptor
antagonists
Proton pump inhibitors
Antibacterials for
systemic use
J01 J01A, J01B Tetracyclines, Amfenicoles Quinolone antibacterials
J01C except J01CR02 Beta-lactam antibacterials except
amoxicilline and enzyme
inhibitor
Amoxiciline and enzyme
inhibitor
Cefalosporins
J01E Sulfonamids and Trimethoprim
J01F Macrolides, lincosamides,
streptogramins
J01X Other antibacterials (e.g. Fusidic
acid)
Antidepressants N06A N06AA09, N06AA02 Amitryptiline, Imipramine Maprotiline,
Clomipramine,
Fluoxetine
N06AA10, N06AB08 Nortriptyline, Fluvoxamine Citalopram, Trazodone,
Venlafaxine, Mirtazapin N06AB05, N06AB06 Paroxetine, Sertraline
Benzodiazepine
derivatives and
related drugs
b
N05BA N05CD07, N05CF02 Temazepam, Zolpidem Triazolam,
Lormetazepam,
Flunitrazepam,
Loprazolam,
Clobazam,
Bromazepam,
Lorazepam, Oxazepam,
Chloordiazepoxide,
Alprazolam, Zopiclone
N05CD N05BA01 Diazepam
N05CF
Drugs for obstructive
airway diseases
R03 R03AC Selective beta-2-adrenoreceptor
agonists
Adrenergis for systemic
use, Theophylline,
Montelukast R03BA, R03BB Glucocorticoids, Anticholinergics
R03BC01 Cromoglicic acid
Oral blood glucose
lowering drugs
A10B A10BB Sulfonamides, urea derivatives Repaglinide,
Thiazolidinediones A10BA02, A10BF01 Metformin, Acarbose
aDrugs of first choice according to the corresponding NHG standard were only suitable for patients without use of NSAIDs. Therefore, for the
index of adherence of the antacids, special DU90% segments had to be calculated for all PTAMs, with the additional postulation that only first
deliveries of selected GPs were included for those patients who had not had a prescription of a NSAID in the preceding 4 months.
bThe valid NHG standard for hypnotics dated from 1992 and was quite obsolete. To better meet the actual standards and recommendations, we
labelled the guideline drugs, recommended by another commonly used standard [23].
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delivery of a drug to a certain patient who, in the
preceding half year, had not had a similar prescription of
the same substance (on fifth ATC level and thereby
regardless of dosage, dosage form, pack size and brand)
[11]. For each FTO group, the first dispensings of the
participating GPs expressed as the number of defined
daily doses (DDDs) per ATC-5 code were calculated
separately within the seven medication groups. Within
each of the seven groups of drugs and for each PTAM, the
substances were ranked by descending volume of DDDs
to estimate DU90% segments for drug utilisation as
described earlier by Bergman et al. [7]. The DU90%
method focuses on 90% of the delivered drug volume. The
borderline of 90% is an arbitrary but useful choice to
study the bulk of prescribing while still allowing some
leeway for individual variation due to special patient
conditions. The DU90% method supplies three general
quality indicators for prescribing [7]. One indicator type
addresses the number of drugs within the DU90% segment
(defined as substance of the same ATC code, fifth level). The
second indicator is based on the percentage of drugs
according to accepted guidelines within the DU90% seg-
ment. The third indicator measures economic aspects by the
relationship between the costs per DDD in the DU90%
segment and the costs per DDD in the remaining segment.
From this, we deduced the following three indicators to
assess the quality of prescribing:
1. Prescribing according to ATC
2. Prescribing according to guidelines
3. Cost-effective prescribing
1. Prescribing according to ATC
Within the DU90% segments of all seven groups of
drugs, it was determined how many substances (fifth ATC
level) accounted for the DU90% segment. Physicians are
expected to manage prescribing by restricting it to a limited
number of drugs. High quality of prescribing is then
associated with the use of a relatively limited number of
pharmaceutical products within a drug group [6]. PTAMs
are expected to come to agreements on the drugs preferred
for treatment of certain diseases. As PTAMs functioning on
a higher level should be more able to make specific choices
and follow these, we expected the number of drugs within a
certain group of drugs to decrease with higher levels of
PTAMs.
2. Prescribing according to guidelines
The national practice guidelines for GPs provide
evidence-based recommendations for drugs of first choice
for average patients with the indication in question. For
each group, drugs were classified as permitted or not
recommended by the guidelines. Classification was done on
the basis of the Dutch Practice Guidelines for GPs (NHG-
standards) valid in 2004 (the Dutch Standards have been
described elsewhere [12]). We made use of the online
accessible updates on the web site of the Dutch organiza-
tion of GPs [13–19]. The particular choices made are listed
in Table 3. Consecutively, the number of DDDs of the
guideline drugs was related to the whole number of DDDs
in the DU90% segment [6]. Better functioning PTAMs are
more likely to come to binding agreements on using drugs
recommended by the guidelines and not for instance
advocated by industrial marketing. We expected the index
of adherence for each group of drugs within the DU90%
segment to increase with higher levels of PTAMs.
3. Cost-effective prescribing
For each ATC code, the actual cost per DDD as cost
price for the pharmacy were recorded at the moment of
dispensing (without value-added tax and regardless of the
amount of reimbursement per prescription or discount).
Per PTAM, the mean cost/DDD were estimated for each
DU90% segment and for the remaining 10% segment of
the seven drug groups. Consecutively, the relationship of
the cost/DDD in the remaining 10% segment and the
DU90% was calculated (cost/DDD of remaining 10%
segment divided by cost/DDD of DU90% segment) [6].
When coming to agreements of drugs to be used
preferably, PTAMs are also expected to take costs into
account. Comparison between the median costs/DDD
within the remaining segment of scarcely prescribed drugs
and the DU90% segment for each of the seven drug
groups is likely to elucidate in how far the drug choices
were also related to costs. As PTAMs on a higher level
were likely to succeed better in consistent cost-effective
choices, we expected the indicator to be increased with
higher levels of PTAMs.
Analyses
Within all three indicator types, mean results (plus
standard deviation) for the seven groups of drugs were
calculated for each PTAM. With univariate and multi-
variate analyses of variance (MANOVA), variation
between the levels of PTAMs was checked for all
indicators of the seven drug groups within all three
types of indicators. With MANOVA, analyses could be
performed for all seven drug groups within one type of
indicator simultaneously, adjusting for the fact that
within a type of indicator, the same PTAMs were
repeatedly measured for outcome of the seven drug
classes. Further, we adjusted for the number of GPs per
PTAM in categories from 1 to 10 GPs, 11 to 20 GPs, 21
to 30 GPs and more than 30 GPs per PTAM. All
analyses were done with SPSS 12.1 for Windows (SPSS,
Chicago, IL, USA).
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Participating PTAMs
From the 387 pharmacies belonging to 257 PTAMs invited
for participation in this study, 182 pharmacies
(corresponding to 122 PTAMs) gave permission to use
their data (47% response). One hundred twenty-two
pharmacists belonging to totally 96 PTAMs identified their
participating GPs (67% of responding pharmacists). Among
these were 11 PTAMs which not had permitted the use of
their data. One pharmacy had switched from computer
system in 2005 so that the codes for the GPs when filling
the web form did not correspond any longer with the data
delivered in 2004. Therefore, the data of the corresponding
PTAM could not be used. For our study, data of 102
pharmacies were available belonging to 84 PTAMs (26% of
the contacted pharmacies and 33% of the invited PTAMs).
The distribution of these PTAMs within the different levels
is shown in Table 4. The number of participating GPs did
not differ significantly between these groups.
Results of the three indicators
1. Prescribing according to ATC
The mean number of drugs within the DU90% segment
for the seven groups of drugs ranged from of 3.1 for the
HMG CoA reductase inhibitors to 9.6 for the antibacterials
for systemic use. Within a certain group of drugs, however,
the number of drugs was quite similar for all levels of
PTAMs (Fig. 1). MANOVA could not detect any differ-
ences in the number of DU90% drugs for the levels of
PTAMs (p=0.144). The number of GPs had no significant
impact on the number of DU90% drugs (p=0.884).
2. Prescribing according to guidelines
The index of adherence to guidelines for the seven
groups of drugs on average ranged from 48% for the drugs
for acid related disorders to 96% for the antibacterials for
systemic use. Within a certain group of drugs, however, the
index of adherence was quite similar for all levels of
PTAMs (Fig. 1). MANOVA could not detect any differ-
ences in the index of adherence for the four levels of
PTAMs (p=0.836). The number of GPs had no significant
impact on the index of adherence (p=0.963).
3. Cost-effective prescribing
The cost per DDD within the DU90% segment on
average ranged from 0.14 €/DDD for the benzodiazepine
derivatives up to 0.99 €/DDD for the antibacterials for
systemic use. In the remaining segment, the cost /DDD
varied from 0.22 €/DDD for the benzodiazepine derivatives
Table 4 Numbers of PTAMs and GPs per level of PTAM
Level of PTAMs Number of PTAMs (%) Number of GPs (SD)
Not classified 7 (8) 6.6 (2.2)
1 21 (25) 10.4 (7.0)
2 23 (27) 8.1 (3.5)
3 15 (18) 9.3 (6.7)
4 18 (27) 10.9 (5.5)
Total 84 (100)
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Fig. 1 Prescribing according to ATC, according to guidelines and cost-effective prescribing for different groups of drugs and all levels of PTAMs
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The relationship between the cost/DDD of the rest segment
and the cost/DDD of the DU90% segment was taken as
indicator. A high result indicated a large difference in costs
for the drugs seldom dispensed compared to those
responsible for 90% of dispensed volume. Except for the
group of the oral blood-glucose-lowering drugs (ratio 3.6),
the groups had mean ratios between 0.9 and 1.8 for the
costs/DDD in the remaining segment divided by the costs/
DDD for the DU90% segment.
MANOVA could not detect any differences in cost
effectiveness for the four levels of PTAMs (p=0.636;
Fig. 1). The number of GPs had no significant impact on
the indicator for cost effectiveness (p=0.744).
Discussion
In this cross-sectional study, we found no association
between the level of functioning of PTAMs and the quality
of prescribing for any drug group within the three indicator
types chosen. Although we made several improvements in
the choice of the prescribing indicators and the quality
assessment of PTAMs compared to earlier studies, our
findings were similar to those of Muijrers et al. [1].
However, these results are counterintuitive to the prevailing
and general opinion that it makes sense to have well-
organised PTAMs. We therefore critically evaluated our
methods and results to see if we could come up with a
plausible explanation for our findings. First of all, we
looked at the selected prescribing indicators. In Sweden, the
selected DU90% method had been used successfully to
assess and distinguish the quality between primary health-
care centres [7]. In our study, however, differences between
the levels of PTAMs turned out to be less substantial than
those between the Swedish healthcare centres [6]. Appar-
ently, the quality of prescribing concerning a restricted
number of drugs, a choice concerning the guidelines and
the cost efficiency in The Netherlands, is generally high
and may approach an optimum in daily practice. This is
quite obvious for the index of adherence found for the oral
blood-glucose-lowering drugs and the antibacterials for
systemic use. In acid-related disorders, however, the
guideline acceptance seemed to be generally low, possibly
due to considerations in daily practice that overall do not
match with the recommendation in the standards. For the
prescribing according to ATC, there is no general agree-
ment on the lowest number possible within one drug class
still warranting a desired level of prescribing quality for the
individual patient. However, the low numbers of drugs
within HMGCoA inhibitors, oral blood-glucose-lowering
agents and agents for acid-related disorders found in our
study seem to represent an overall high quality of
prescribing. The cost-effectiveness was also overall high
for oral blood-glucose-lowering drugs which was the only
drug class with substantial differences in costs/DDDs.
Possibly due to high quality of prescribing for these three
aspects in general, our three indicator types were not
suitable to detect differences in the quality of prescribing
for different levels of functioning in PTAMs. To distinguish
the quality of drug prescribing in our country, indicators
should be more sophisticated and address specific aspects
in the daily practice of good prescribing within each drug
class [9]. For instance, with antidepressants, the suitable
duration of treatment may be more relevant for good
prescribing than using the first drug choice from the
guidelines [20]. In diabetes, the supply of HMGCoA
reductase inhibitors as co-medication may be more impor-
tant than the number of different oral blood-glucose-
lowering drugs [21]. For obstructive airway diseases,
co-prescribing and concordance with corticosteroids is
more decisive for patients prognosis than choices according
to guidelines [22]. Second, in using the DU90% method,
the estimation of segments may need further specification,
especially for the aspect of cost effectiveness. As DDDs in
general are not always equipotent and may not, in all cases,
represent the prescribed daily practice, the costs of the
DU90% may be misclassified. For atorvastatin for instance,
normally two DDDs are used as daily dosage. Based on the
DDD classification, the DU90% volume in our study
overestimated the volume of HMGCoA reductase inhibitors
and underestimated the costs per effective DDD.
We also looked at the tool for measuring the quality of
PTAM. This tool was based on criteria that had been valued
as crucial and suitable by an expert panel and had been
proven to be applicable in practice [4]. However, other
criteria than the selected ones might be more decisive for
public health. An example of an additional criterion is the
one Florentinus et al. [2] found to be related with the
quality of prescribing, namely to agree on one representa-
tive within a PTAM to receive the visitors of the
pharmaceutical industry. Evaluation of the classification of
PTAM levels of 2004 showed that only half of the PTAMs,
being able to make and to evaluate decisions, actually were
classified as the highest level. The main reasons for a lower
classification were due to the lack of meeting the criteria on
the number and duration of meetings. However, PTAMs
meeting less than five times per year and being in
conference for less than 1.5 h might be quite able to make
and fulfil agreements on high quality of prescribing. Thus,
the functioning of PTAMs may have been underestimated
in our study, which may explain that also PTAMs of lower
levels were able to reach high scores in the quality of
prescribing.
Another possible explanation could be selection bias
caused by the voluntary participation in our study which
1176 Eur J Clin Pharmacol (2007) 63:1171–1177was quite low. In 2004, there were in total 824 PTAMs in
The Netherlands, of which, 14% were in level 1, 43% were
in level 2, 20% were in level 3 and 23% were in the highest
level 4. Due to our stratified invitation of 50 groups from
each level and 57 groups of no classified level, we managed
to include sufficient numbers within each level. On
average, PTAMs in The Netherlands had 9.6 GPs, compa-
rable to the number of participating PTAMs in our study.
Only a quarter of the pharmacists corresponding with one
third of the PTAMs invited finally succeeded in participa-
tion. Possibly, by this, we included primarily those PTAMs
being well organised and with a high level of cooperation
regardless of the quality level assessed. The classification
into the different PTAM levels might not have created
substantial differentiation between participating groups, and
this could be an explanation for the fact that the results of
our indicators were nearly the same for the different PTAM
levels.
A further limitation was our lack of information about
the topics that have actually been discussed by the PTAMs
in 2004 and earlier. It is possible that PTAMs made
agreements on other aspects than the three indicator types
chosen. Perhaps, agreements were made on the duration of
treatment with antidepressants, on co-medication with
HMGCoA inhibitors in patients with diabetes or on usage
of new drugs, but as mentioned above, these were not
measured by our three indicator types.
In conclusion, it is difficult to define indicators based on
the DU90% method that can readily distinguish differences
in the quality of drug prescribing between PTAMs with
different levels of functioning. Indicators have to be more
sophisticated and to meet relevant aspects of the pharma-
cotherapy within certain drug classes. Items for classifica-
tion of PTAM levels may need some reconsideration.
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